Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Many trials exclude certain groups, and do so deliberately—children, for example, or people with physical or learning ...

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

We have produced resources about lecanemab for you and your patients. Find out more below. Donanemab (brand name Kisunla®) is a new medication used to treat the very early stages of Alzheimer's ...

Rather than seeking a single cure — a magic bullet — for Alzheimer’s disease, a shotgun blast of different drugs with ...

Initiative will eliminate up to 25% of all reauthorizations, or 10% of overall prior authorizations, PBM says.

DiADeM is a tool to support GPs in diagnosing dementia for people living with advanced dementia in a care home setting. It has been developed by the Yorkshire and Humber Dementia Strategic Clinical ...

Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...